|Mr. Wern-Yi Goh B.Com., M.B.A.||CEO & Director||240k||N/A||1967|
|Mr. Lars Birkmann||Chief Financial Officer||N/A||N/A||1978|
|Mr. David John Cleveland Hodge||Head of Corp. Devel.||N/A||N/A||1960|
|Mr. Chunhyok Chong||Head of Devel.||N/A||N/A||1973|
|Mr. Windiaprana Ramelan||Head of Operations Asia||N/A||N/A||1970|
|Mikko Tirronen||Head of Operations Europe||N/A||N/A||N/A|
|Mr. Richard Lingard||Sr. VP of Commercialisation||N/A||N/A||N/A|
|Mr. Kiki Rizki||Gen. Mang. of Indonesia||N/A||N/A||N/A|
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. The company's lead product is AptameX, a rapid test that uses DNA aptamers instead of antigens to detect the SARS-CoV-2 virus. It also offers Teman Sehat, a mobile check-in and passport application. In addition, the company provides secure payment solutions for game publishers and application developers to accept various payment methods for digital contents and goods under the Mimopay brand, as well as develops game software. Achiko AG was incorporated in 2018 and is headquartered in Zurich, Switzerland.
Achiko AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.